Ekso Bionics Holdings Inc
NASDAQ:EKSO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Ekso Bionics Holdings Inc
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in Richmond California, California and currently employs 45 full-time employees. The company went IPO on 2013-04-10. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The firm operates in two segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform repetitive work. Its products include EksoNR and EksoUE. EksoNR is a rehabilitation device that assists physical therapists and physicians to treat patients who have suffered an acquired brain injury, stroke or spinal cord injury. EksoUE is a wearable upper body exoskeleton that assists patients with a broad range of upper extremity impairments.
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in Richmond California, California and currently employs 45 full-time employees. The company went IPO on 2013-04-10. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The firm operates in two segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform repetitive work. Its products include EksoNR and EksoUE. EksoNR is a rehabilitation device that assists physical therapists and physicians to treat patients who have suffered an acquired brain injury, stroke or spinal cord injury. EksoUE is a wearable upper body exoskeleton that assists patients with a broad range of upper extremity impairments.
Revenue Miss: Q2 2025 revenue fell to $2.1 million from $5 million in Q2 2024 due to delays in multi-device Enterprise Health sales, which management views as temporary.
Margin Pressure: Gross margin dropped to 40% from 53% a year ago, primarily due to fixed costs on lower sales volume and increased distribution and shipping costs.
Expense Control: Operating expenses declined 4% year-over-year to $4.8 million, reflecting some cost discipline.
Personal Health Growth: Revenues from Ekso Indego Personal grew over 50% in the first half of 2025, partially offsetting declines in the legacy Enterprise Health segment.
Deferred Sales Pipeline: Management expects to close most of the $1.4 million in delayed Enterprise Health deals before year-end, with a major $1 million order targeted for Q3.
AI & Innovation: The company is investing in AI, launching a new partnership with NVIDIA Connect and revealing an AI voice agent for its flagship device.
Guidance Maintained: Despite Q2 weakness, management remains confident about a stronger second half and sees growing contribution from Personal Health products.
